The following article was reprinted with permission from Medical Economics magazine, another of Advanstar Medical Economics Healthcare publications. Weiss is senior editor of Medical Economics. For more information on the article, please visit Medical Economics MagazineYour receptionist lets you know that a Dr. Smith is on the phone, and he's checking the references of Jane Miller, a former staffer. You and your employees are thrilled that Jane no longer works for you. She was chronically late, sloppy, rude to patients, and was about to be fired when she quit, ostensibly for family reasons, about a year ago. "What should I tell him? Do you want to talk to him?"
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.